| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -4,312 | 27,225 |
| Accretion of discount on investments | 1,744 | 1,034 |
| Non cash lease expense | 1,383 | 905 |
| Change in fair value of 2023 common warrants | -58,971 | -63,176 |
| Depreciation expense | 673 | 453 |
| Stock-based compensation including espp | 3,586 | 2,119 |
| Other assets | -777 | -190 |
| Accounts payable | 2,080 | 1,328 |
| Accrued liabilities | -1,952 | -3,352 |
| Operating lease liabilities | -2,295 | -1,499 |
| Deferred revenue | 17 | 428 |
| Net cash and cash equivalents used in operating activities | -60,758 | -36,413 |
| Maturities of short-term investments | 90,000 | 20,000 |
| Purchase of short-term investments | 125,460 | 103,336 |
| Purchases of property and equipment | -345 | -152 |
| Net cash and cash equivalents used in investing activities | -35,805 | -83,488 |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with pipe offering, net of costs | 101,343 | 101,386 |
| Payments on finance lease | 11 | 1 |
| Proceeds from the espp purchase | 180 | 180 |
| Net cash and cash equivalents provided by financing activities | 101,512 | 101,565 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 4,949 | -18,336 |
| Cash and cash equivalents at beginning of period | 37,107 | - |
| Cash and cash equivalents at end of period | 42,056 | - |
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)